These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32934022)

  • 1. Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies.
    Park DS; Luddy KA; Robertson-Tessi M; O'Farrelly C; Gatenby RA; Anderson ARA
    Cancer Res; 2020 Dec; 80(23):5147-5154. PubMed ID: 32934022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations.
    Ferrer F; Fanciullino R; Milano G; Ciccolini J
    Clin Pharmacol Ther; 2020 Sep; 108(3):458-470. PubMed ID: 32557660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-driven management strategies for peripheral T cell lymphoma.
    Mulvey E; Ruan J
    J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Targeting of Cancer Cells and Tumor Microenvironment: Perspectives for Personalized Therapy.
    Kzhyshkowska J; Bizzarri M; Apte R; Cherdyntseva N
    Curr Pharm Des; 2017; 23(32):4703-4704. PubMed ID: 29283049
    [No Abstract]   [Full Text] [Related]  

  • 5. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A theoretical quantitative model for evolution of cancer chemotherapy resistance.
    Silva AS; Gatenby RA
    Biol Direct; 2010 Apr; 5():25. PubMed ID: 20406443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
    Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
    Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right.
    Park DS; Robertson-Tessi M; Luddy KA; Maini PK; Bonsall MB; Gatenby RA; Anderson ARA
    Cancer Res; 2019 Oct; 79(20):5302-5315. PubMed ID: 31387920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion.
    D'Alterio C; Scala S; Sozzi G; Roz L; Bertolini G
    Semin Cancer Biol; 2020 Feb; 60():351-361. PubMed ID: 31454672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine.
    Wang Z; Liu X; Ho RL; Lam CW; Chow MS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27399658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
    Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
    Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
    Hamis S; Nithiarasu P; Powathil GG
    J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
    Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
    Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one.
    Peterson GM; Thomas J; Yee KC; Kosari S; Naunton M; Olesen IH
    J Clin Pharm Ther; 2018 Dec; 43(6):925-930. PubMed ID: 30047144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.